DYR726

DYR726 is a water-soluble, pleiotropic small molecule kinase inhibitor (SKMI) being developed for the treatment of glioblastoma multiforme (GBM). It acts as a multi-kinase inhibitor targeting several pro-survival signaling pathways prominently involved in GBM cell proliferation, survival, and resistance, including the dual-specificity tyrosine-phosphorylation-regulated kinases (DYRK1A, DYRK2, and DYRK3), CDC-like kinases (CLK2 and CLK3), platelet-derived growth factor receptors (PDGFRA and PDGFRB), and the catalytic subunit of phosphoinositide 3-kinase alpha (PI3Kα). In preclinical studies, DYR726 has demonstrated potent in vitro efficacy across various GBM cell lines, showing superior or comparable activity to clinical candidates like buparlisib and avapritinib. It effectively dissociates neural stem cell formation and inhibits neurosphere growth. The compound is being advanced as a potential Phase 0 clinical candidate within the framework of the CRUK Glasgow Cancer Center.